Jm. Bachaud et al., COMBINED POSTOPERATIVE RADIOTHERAPY AND WEEKLY CISPLATIN INFUSION FORLOCALLY ADVANCED HEAD AND NECK-CARCINOMA - FINAL REPORT OF A RANDOMIZED TRIAL, International journal of radiation oncology, biology, physics, 36(5), 1996, pp. 999-1004
Citations number
25
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: To report the final results of a prospective randomized trial
that aimed to evaluate efficacy and toxicity of concomitant postopera
tive radiotherapy and Cisplatin infusion in patients with Stage III or
IV squamous cell carcinoma of the head and neck and histological evid
ence of extracapsular spread of tumor in lymph node metastase(s). Meth
ods and Materials: Radiotherapy was delivered using a daily dose of 1.
7 Gy for the first 54 Gy and 1.8 to 2 Gy until the completion of the t
reatment. Cisplatin 50 mg i.v. with forced hydratation was given or no
t every week (i.e., seven to nine cycles) concurrently with radiothera
py, A total of 44 patients were treated by irradiation only (RT group)
and 39 by irradiation with chemotherapy (CM group). Results: The RT g
roup displayed a higher rate of loco-regional failures as compared to
CM group (41 vs. 23%; p = 0.08). The overall survival, the survival co
rrected for deaths by intercurrent disease, and the disease-free survi
val were better in CM group as compared to RT group with statistically
significant differences. Survival without loco-regional treatment fai
lure was better in the CM group, the difference being close to the lev
el of significance (p = 0.05). Survival without distant metastases wer
e comparable in the two therapeutic groups. Ten severe late complicati
ons were observed, four in the RT group (17%) and six in the CM group
(22%). Cox univariate analysis confirmed the importance of the therape
utic modality in predicting the overall survival, the survival correct
ed for deaths by intercurrent disease, and the disease-free survival.
Conclusions: The present final report of this phase III study confirms
preliminary results. The concomitant use of 50 mg weekly Cisplatin in
fusion and postoperative radiation improved loco-regional control and
survival. No significant increase of late radiation complications was
observed in the CM group. Copyright (C) 1996 by Elsevier Science Inc.